Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01434498 · ClinicalTrials.gov registry record · Phase 2
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT01434498 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 163 participants.
The verdict
NCT01434498, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects with Chronic Genotype 1a or 1b HCV Infection.
Interventions
- DRUG ribavirin tablet
- DRUG GS-5885 tablet
- DRUG GS-9451 tablet
- DRUG tegobuvir capsule
- DRUG placebo matching ribavirin tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01434498
The ClinicalTrials.gov registry entry for NCT01434498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ribavirin tablet is the first listed.
NCT01434498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01434498 about?
NCT01434498 is a clinical study titled "GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection". This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects with Chronic Genotype 1a or 1b HCV Infection.
What is the current status of trial NCT01434498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2011-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01434498?
The interventions under investigation include: ribavirin tablet (DRUG), GS-5885 tablet (DRUG), GS-9451 tablet (DRUG), tegobuvir capsule (DRUG), placebo matching ribavirin tablet (DRUG).
Who is sponsoring clinical trial NCT01434498?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.